NCT02486120

Completed

Are Genetic Counselors Screening for Adolescent Suicide Risk...

National Human Genome Research Institute (NHGRI)Source

Compare

Other study identifiers

Sponsor study identifier

999915152

Secondary identifiers

15-HG-N152

Study Type

observational

Actual enrollment (reported)

267

Locations

1 country

Sites

1

Timeline

Study Start

June 22, 2015

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 31, 2016

Actual (reported)

Study Completion

May 24, 2017

Actual (reported)

Brief Summary

Background: \- Suicide is one of the main causes of death for adolescents in the U.S. The most effective way to decrease suicide is by training doctors to recognize the risk factors in their clients. One risk factor for suicide is chronic illness. So pediatric genetic counselors come across high-risk clients. But the suicide risk assessment (SRA) practices of these counselors are not well known. Researchers want to study learn more about this. Objectives: \- To describe the practices, attitudes, and beliefs of genetic counselors about SRA of adolescents. Eligibility: \- Genetic counselors who see adolescents ages 10 21 Design:

A study will be open to a listserv for genetic counselors.
Participants will take a survey on their own.
The survey will be online on a secure website.
Participants will give data about themselves. This can include age, gender, job, etc.
The survey will be about 60 questions.
The survey will take around 20 25 minutes.
The questions are about participants experiences, practices, attitudes, and beliefs about SRA.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 267 participants
Study completion date: May 24, 2017
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 22, 2015
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
June 30, 2015
Actual (reported)
First Posted
July 1, 2015
Actual (reported)
Primary Completion
May 31, 2016
Actual (reported)
Study Completion
May 24, 2017
Actual (reported)

Last Updated: October 23, 2019
Status Verified: May 24, 2017
Last Update Submitted: October 22, 2019

Conditions

Healthy Volunteers

Keywords

Genetic CounselingClinical Decision-Making

Outcome Measures

Primary Outcomes (1)

Previous performance of adolescent patient suicide risk assessment
Ongoing

Eligibility Criteria

Age18 Years - 100 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Participants in this study will be English speaking women and men who are graduates of accredited genetic counseling programs. Those who currently or within the past year have worked in-person with adolescent patients between the ages of 10 and 21 may be included in the survey.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

National Human Genome Research Institute (NHGRI)
NIHlead

Study Sites (1)

National Human Genome Research Institute (NHGRI), 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Study Officials

Lori Erby, Ph.D.
National Human Genome Research Institute (NHGRI)
PRINCIPAL INVESTIGATOR

Enrollment

267 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: CROSS SECTIONAL
Sponsor Type: NIH
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 30, 2015

First Posted

July 1, 2015

Study Start

June 22, 2015

Date type not reported

This date has not been verified as actual or estimated.

NCT02415790

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Phase 1Completed

NCT02486809

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Phase 1Completed

NCT02509117

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Phase 1Completed

NCT02516618

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Phase 1Completed

NCT02545439

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

Phase 1Completed

NCT02606682

Phase 1 Study of NPT200-11 in Healthy Subjects

Phase 1Completed

Primary Completion

May 31, 2016

Actual (reported)

Study Completion

May 24, 2017

Actual (reported)

Last Updated

October 23, 2019

Record last verified: 2017-05-24

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02486120
Data provider: ClinicalTrials.gov
Source updated: 2019-10-23
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:01 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations